Michael Oropallo is an experienced immunologist with a comprehensive background in both research and leadership roles. At Merck from July 2017 to June 2025, Oropallo served as Director, Principal Scientist, and Associate Principal Scientist, focusing on developing and characterizing novel models to predict immune system-related adverse events for biologics and small molecules. Prior to this, as a postdoctoral fellow at the Icahn School of Medicine at Mount Sinai (September 2013 to June 2015), Oropallo managed independent research on B and T cell mucosal immunology, innovating methods to isolate rare antibodies and engaging in collaborative projects. Oropallo also completed doctoral studies at the University of Pennsylvania (September 2007 to July 2013), where research centered on B cell tolerance mechanisms and autoimmunity, following a Bachelor of Science degree in Biology from The College of New Jersey, graduating Magna Cum Laude.
This person is not in any teams
This person is not in any offices